

Neon Therapeutics Logo

## Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference

February 21, 2019

CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O'Dowd, Chief Executive Officer of Neon, will present at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019 at 9:00 a.m. ET.

A live webcast of the presentation will be available by visiting the Investors section of Neon Therapeutics' website at [ir.neontherapeutics.com](http://ir.neontherapeutics.com). A replay of the webcast will be archived on the Neon Therapeutics website for 30 days following the presentation.

### About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical-stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.

For more information, please visit [www.neontherapeutics.com](http://www.neontherapeutics.com).

### Media Contact:

Stephanie Simon, Ten Bridge Communications  
[stephanie@tenbridgecommunications.com](mailto:stephanie@tenbridgecommunications.com)  
617-581-9333

### Investor Contact:

Will O'Connor, Stern Investor Relations  
[will@sternir.com](mailto:will@sternir.com)  
212-362-1200



Source: Neon Therapeutics, Inc.